HVAX Technologies Ltd

AI

HVAX Technologies Ltd

₹ 646 1.67%
16 Sep - close price
About

Established in 2010, HVAX Technologies Limited provides turnkey engineering, procurement, and execution of controlled environment and cleanroom infrastructure, design, engineering, and consulting services to pharmaceutical and healthcare companies.[1]

Key Points

Business Profile[1] The company supplies a range of products manufactured by third parties, including cleanroom wall and ceiling panels, covings, riser panels, cleanroom doors, flooring systems, pass boxes, air showers, LT/HT electrical panels, prefabricated galvanized iron (GI) ducts, air handling units, chillers, Building Management Systems (BMS) equipment, and utility generation and distribution equipment.

  • Market Cap 179 Cr.
  • Current Price 646
  • High / Low 1,007 / 585
  • Stock P/E 12.5
  • Book Value 312
  • Dividend Yield 0.00 %
  • ROCE 20.1 %
  • ROE 18.0 %
  • Face Value 10.0

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Earnings include an other income of Rs.7.11 Cr.
  • Company has high debtors of 191 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2026
103
93
Operating Profit 11
OPM % 10%
5
Interest 2
Depreciation 1
Profit before tax 13
Tax % 25%
10
EPS in Rs 33.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
131 164
112 147
Operating Profit 19 17
OPM % 14% 10%
0 7
Interest 2 3
Depreciation 2 1
Profit before tax 15 20
Tax % 26% 25%
11 15
EPS in Rs 39.76 51.53
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 25%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 30%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -15%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Equity Capital 3 3
Reserves 69 84
28 41
22 27
Total Liabilities 122 154
8 7
CWIP 0 0
Investments 0 0
114 147
Total Assets 122 154

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
-22 -14
0 -1
31 10
Net Cash Flow 10 -5
Free Cash Flow -22 -15
CFO/OP -102% -53%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Debtor Days 199 191
Inventory Days 95 147
Days Payable 72 74
Cash Conversion Cycle 222 265
Working Capital Days 146 164
ROCE % 20%

Insights

In beta
Mar 2010 Mar 2012 Mar 2016 Mar 2020 Mar 2023 Mar 2024 Mar 2025
Number of Countries Served
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
International Revenue Share
% ・Standalone data
Cumulative Projects Executed
Count ・Standalone data
Number of Professionals
Count ・Standalone data
Pharmaceutical Sector Revenue Share
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
66.65% 66.65% 66.65% 66.65% 66.65% 66.65% 66.65%
9.35% 9.29% 9.17% 9.13% 8.96% 8.90% 8.90%
0.41% 0.70% 1.13% 1.08% 1.08% 1.08% 1.08%
23.60% 23.36% 23.05% 23.14% 23.31% 23.38% 23.38%
No. of Shareholders 535508463448428425422

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents